Literature DB >> 22430899

Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.

Borja Suberviola1, Alvaro Castellanos-Ortega, Javier Llorca, Fernando Ortiz, David Iglesias, Belen Prieto.   

Abstract

PRINCIPLES: Midregional proadrenomedullin (proADM) is a novel biomarker with potential prognostic utility in patients with community-acquired pneumonia. The aim of this study was to investigate the value of proADM levels for severity assessment and outcome prediction in severe sepsis and septic shock due to CAP.
METHODS: Prospective observational study including 49 patients admitted to ICU with both a clinical and radiologic diagnosis of pneumonia and fulfilling criteria for severe sepsis or septic shock. The prognostic accuracy of proADM levels was compared with those of pneumonia severity index and of procalcitonin (PCT) and C-reactive protein (CRP).
RESULTS: 49 patients with severe sepsis or septic shock due to CAP were included in the study. Mortality was 24.5% for ICU and 34.7% for hospital mortality. In all cases proADM values at ICU admission were pathological (considering normal proADM levels <4 nmol/L). ProADM consistently rose as PSI class advanced from II to V (p = 0.02). Median proADM levels were higher (p <0.01) in hospital non-survivors 5.0 (1.9-10.1) nmol/L vs. survivors 1.7 (1.3-3.1) nmol/L. These differences were also significant with respect to ICU mortality. The receiver-operating characteristic curve for proADM yielded an AUC of 0.72; better than the AUC for PCT and CRP (0.40 and 0.44 respectively) and similar to PSI (0.74).
CONCLUSIONS: In our study MR-proADM levels correlate with increasing severity of illness and death. High MR-proADM levels offer additional risk stratification in high-risk CAP patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22430899     DOI: 10.4414/smw.2012.13542

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  20 in total

1.  Evaluation and significance of C-reactive protein in the clinical diagnosis of severe pneumonia.

Authors:  Jianjun Wu; Y U Jin; Hailong Li; Zhiping Xie; Jinsong Li; Yuanyun Ao; Zhaojun Duan
Journal:  Exp Ther Med       Date:  2015-05-12       Impact factor: 2.447

Review 2.  Are there new approaches for diagnosis, therapy guidance and outcome prediction of sepsis?

Authors:  Dubravka Kojic; Benedikt H Siegler; Florian Uhle; Christoph Lichtenstern; Peter P Nawroth; Markus A Weigand; Stefan Hofer; Thorsten Brenner
Journal:  World J Exp Med       Date:  2015-05-20

3.  Adrenomedullin: a vasodilator to treat sepsis?

Authors:  Jérôme Pugin
Journal:  Crit Care       Date:  2014-06-16       Impact factor: 9.097

Review 4.  Role of complement C5a and histones in septic cardiomyopathy.

Authors:  Fatemeh Fattahi; Lynn M Frydrych; Guowu Bian; Miriam Kalbitz; Todd J Herron; Elizabeth A Malan; Matthew J Delano; Peter A Ward
Journal:  Mol Immunol       Date:  2018-06-18       Impact factor: 4.407

Review 5.  New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure.

Authors:  Francisco Valenzuela-Sánchez; Blanca Valenzuela-Méndez; Juan Francisco Rodríguez-Gutiérrez; Ángel Estella-García; María Ángela González-García
Journal:  Ann Transl Med       Date:  2016-09

Review 6.  Novel Biomarkers to Detect Target Organ Damage in Acute Hypertension.

Authors:  Stephen Boone; Dick Kuo
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

7.  Performance evaluation of MR-proadrenomedullin and other scoring systems in severe sepsis with pneumonia.

Authors:  Serdar Akpinar; Kazım Rollas; Ali Alagöz; Fatih Seğmen; Tuğrul Sipit
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

Review 8.  [Use of biomarkers in sepsis. Update and perspectives].

Authors:  B H Siegler; S Weiterer; C Lichtenstern; D Stumpp; T Brenner; S Hofer; M A Weigand; F Uhle
Journal:  Anaesthesist       Date:  2014-09       Impact factor: 1.041

Review 9.  Complement and sepsis-induced heart dysfunction.

Authors:  Fatemeh Fattahi; Peter A Ward
Journal:  Mol Immunol       Date:  2016-12-05       Impact factor: 4.407

10.  Biomarkers in Shock Patients and Their Value as A Prognostic Tool; A Prospective Multi-Center Cohort Study.

Authors:  Ana Maria Navio Serano; Joaquín Valle Alonso; Gustavo Rene Piñero; Alejandro Rodriguez Camacho; Josefa Soriano Benet; Manuel Vaquero
Journal:  Bull Emerg Trauma       Date:  2019-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.